Terms: = Ovarian cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551
138 results:
1. A computer synoptic operative report versus a report dictated by a surgeon in advanced ovarian cancer.
Bedel A; Blache G; Jauffret C; Houvenaeghel G; Buttarelli M; Sabiani L; Mokarram Dorri N; El Hajj H; Lambaudie E
Int J Gynecol Cancer; 2024 Apr; 34(4):581-585. PubMed ID: 38336374
[TBL] [Abstract] [Full Text] [Related]
2. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
3. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
Li R; Liu X; Huang X; Zhang D; Chen Z; Zhang J; Bai R; Zhang S; Zhao H; Xu Z; Zeng L; Zhuang L; Wen S; Wu S; Li M; Zuo Z; Lin J; Lin D; Zheng J
Gut; 2024 Feb; 73(3):470-484. PubMed ID: 38050068
[TBL] [Abstract] [Full Text] [Related]
4. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract] [Full Text] [Related]
5. Charge-conversional click polyprodrug nanomedicine for targeted and synergistic cancer therapy.
Wang Y; Cong Y; Cai M; Liang X; Wang L; Zhou D
J Control Release; 2023 Apr; 356():567-579. PubMed ID: 36924894
[TBL] [Abstract] [Full Text] [Related]
6. Glutathione Transferase P1: Potential Therapeutic Target in ovarian cancer.
Simic P; Pljesa I; Nejkovic L; Jerotic D; Coric V; Stulic J; Kokosar N; Popov D; Savic-Radojevic A; Pazin V; Pljesa-Ercegovac M
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422199
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis.
Xia X; Li Z; Li Y; Ye F; Zhou X
J Gynecol Oncol; 2022 Nov; 33(6):e81. PubMed ID: 36335987
[TBL] [Abstract] [Full Text] [Related]
8. Acoustic triggered nanobomb for US imaging guided sonodynamic therapy and activating antitumor immunity.
Li M; Zhu Y; Yang C; Yang M; Ran H; Zhu Y; Zhang W
Drug Deliv; 2022 Dec; 29(1):2177-2189. PubMed ID: 35815688
[TBL] [Abstract] [Full Text] [Related]
9. Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.
Houvenaeghel G; de Nonneville A; Blache G; Buttarelli M; Jauffret C; Mokart D; Sabiani L
J Gynecol Oncol; 2022 May; 33(3):e31. PubMed ID: 35320883
[TBL] [Abstract] [Full Text] [Related]
10.
Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
[TBL] [Abstract] [Full Text] [Related]
11. P1 promoter IGF-1 polymorphism and IGF-1, IGF-R, LSF, and TSG 101 expression profile in endometriosis.
Kwasniewski W; Stupak A; Wolun-Cholewa M; Fronczek A; Kwasniewska A; Kotarski J; Polak G; Gozdzicka-Jozefiak A
Ginekol Pol; 2022; 93(10):775-786. PubMed ID: 35072229
[TBL] [Abstract] [Full Text] [Related]
12. [A Case of Isolated Metachronous Splenic Metastasis after Rectal cancer Surgery].
Kuboyama Y; Sumi T; Sahara Y; Fukushima G; Matsumoto M; Matsudo T; Tachibana S; Mimuro H; Ishibashi Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1688-1690. PubMed ID: 35046298
[TBL] [Abstract] [Full Text] [Related]
13. MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues.
Yao T; Rudak PT; Laumont CM; Michaud AR; Rashu R; Knier NN; Foster PJ; McWilliam HEG; Villadangos JA; Nelson BH; DiMattia GE; Shepherd TG; Haeryfar SMM
Cancer Immunol Immunother; 2022 May; 71(5):1259-1273. PubMed ID: 34854949
[TBL] [Abstract] [Full Text] [Related]
14. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract] [Full Text] [Related]
15. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Basaran D; Boerner T; Suhner J; Sassine D; Liu Y; Grisham RN; Tew WP; Gardner GJ; Zivanovic O; Sonoda Y; Long Roche K; Chi DS; Abu-Rustum NR; Soff GA; Jewell EL
Gynecol Oncol; 2021 Oct; 163(1):36-40. PubMed ID: 34312001
[TBL] [Abstract] [Full Text] [Related]
16. NIR Laser Responsive Nanoparticles for ovarian cancer Targeted Combination Therapy with Dual-Modal Imaging Guidance.
Zhao J; Zhang L; Qi Y; Liao K; Wang Z; Wen M; Zhou D
Int J Nanomedicine; 2021; 16():4351-4369. PubMed ID: 34234430
[TBL] [Abstract] [Full Text] [Related]
17. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract] [Full Text] [Related]
18. Bis-conjugation of Bioactive Molecules to Cisplatin-like Complexes through (2,2'-Bipyridine)-4,4'-Dicarboxylic Acid with Optimal Cytotoxicity Profile Provided by the Combination Ethacrynic Acid/Flurbiprofen.
Biancalana L; Batchelor LK; Pereira SAP; Tseng PJ; Zacchini S; Pampaloni G; Saraiva LMFS; Dyson PJ; Marchetti F
Chemistry; 2020 Dec; 26(72):17525-17535. PubMed ID: 33252170
[TBL] [Abstract] [Full Text] [Related]
19. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract] [Full Text] [Related]
20. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract] [Full Text] [Related]
[Next]
